(Q36513911)

14 August 2017

1 reference

title

Antihypertensive therapy: taking lipids into consideration (English)

1 reference

14 August 2017

Antihypertensive therapy: Taking lipids into consideration (English)

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Cardiology and cardiovascular medicine

27 October 2022

main subject

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

27 October 2022

author name string

Grimm RH Jr

1

1 reference

14 August 2017

R. H. Grimm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1678922

27 October 2022

language of work or name

English

0 references

publication date

1 September 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:000287039190811U?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

https://api.elsevier.com/content/article/PII:000287039190811U?httpAccept=text/plain

27 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

27 October 2022

published in

American Heart Journal

1 reference

14 August 2017

volume

122

1 reference

14 August 2017

issue

3 Pt 2

1 reference

14 August 2017

page(s)

910-918

1 reference

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

27 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Effects of antihypertensive therapy on plasma lipids and lipoproteins in the multiple risk factor intervention trial

27 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial

27 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Effect of chronic administration of propranolol on lipoprotein composition

27 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Metabolic consequences of atenolol and propranolol in treatment of essential hypertension

27 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Comparative effects of prazosin and atenolol on plasma lipids in hypertensive patients

27 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

alpha 1-antagonists in the treatment of hypertension

27 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Antihypertensive treatment and serum lipoproteins

27 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

The effects of terazosin and methyclothiazide on blood pressure and serum lipids

27 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Concomitant administration of terazosin and atenolol for the treatment of essential hypertension

27 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Suppositions and speculations--their possible effects on treatment decisions in the management of hypertension

27 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

In defense of traditional antihypertensive therapy

27 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Lipid abnormalities and diuretics

27 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Relative efficacy of, and some adverse reactions to, different antihypertensive regimens

27 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants

27 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension

27 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial

27 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone

27 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Antihypertensive treatment and plasma lipoprotein levels. The associations in data from a population study

27 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

27 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

27 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

27 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

27 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

27 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

27 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Blood pressure, stroke, and coronary heart disease

27 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial

27 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Benefits and potential harm of lowering high blood pressure

27 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension

27 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS)

27 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90811-U

27 October 2022

Identifiers

1 reference

14 August 2017

1 reference